| pubmed-article:16030067 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0242692 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0391690 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C1540067 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C0293969 | lld:lifeskim |
| pubmed-article:16030067 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:16030067 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16030067 | pubmed:dateCreated | 2005-11-10 | lld:pubmed |
| pubmed-article:16030067 | pubmed:abstractText | Chronic arthritis is a catabolic state associated with an inhibition of the IGF system and a decrease in body weight. Cachexia and muscular wasting is secondary to protein degradation by the ubiquitin-proteasome pathway. The aim of this work was to analyze the effect of adjuvant-induced arthritis on the muscle-specific ubiquitin ligases muscle ring finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) as well as on IGF-I and IGF-binding protein-5 (IGFBP-5) gene expression in the skeletal muscle. We also studied whether the synthetic ghrelin receptor agonist, growth hormone releasing peptide-2 (GHRP-2), was able to prevent arthritis-induced changes in the skeletal muscle. Arthritis induced an increase in MuRF1, MAFbx (P < 0.01), and tumor necrosis factor (TNF)-alpha mRNA (P < 0.05) in the skeletal muscle. Arthritis decreased the serum IGF-I and its gene expression in the liver (P < 0.01), whereas it increased IGF-I and IGFBP-5 gene expression in the skeletal muscle (P < 0.01). Administration of GHRP-2 for 8 days prevented the arthritis-induced increase in muscular MuRF1, MAFbx, and TNF-alpha gene expression. GHRP-2 treatment increased the serum concentrations of IGF-I and the IGF-I mRNA in the liver and in the cardiac muscle and decreased muscular IGFBP-5 mRNA both in control and in arthritic rats (P < 0.05). GHRP-2 treatment increased muscular IGF-I mRNA in control rats (P < 0.01), but it did not modify the muscular IGF-I gene expression in arthritic rats. These data indicate that arthritis induces an increase in the activity of the ubiquitin-proteasome proteolytic pathway that is prevented by GHRP-2 administration. The parallel changes in muscular IGFBP-5 and TNF-alpha gene expression with the ubiquitin ligases suggest that they can participate in skeletal muscle alterations during chronic arthritis. | lld:pubmed |
| pubmed-article:16030067 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16030067 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16030067 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16030067 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16030067 | pubmed:issn | 0193-1849 | lld:pubmed |
| pubmed-article:16030067 | pubmed:author | pubmed-author:MartínAna IAI | lld:pubmed |
| pubmed-article:16030067 | pubmed:author | pubmed-author:PriegoTeresaT | lld:pubmed |
| pubmed-article:16030067 | pubmed:author | pubmed-author:López-Calderó... | lld:pubmed |
| pubmed-article:16030067 | pubmed:author | pubmed-author:GranadoMiriam... | lld:pubmed |
| pubmed-article:16030067 | pubmed:author | pubmed-author:VillanúaMaria... | lld:pubmed |
| pubmed-article:16030067 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16030067 | pubmed:volume | 289 | lld:pubmed |
| pubmed-article:16030067 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16030067 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16030067 | pubmed:pagination | E1007-14 | lld:pubmed |
| pubmed-article:16030067 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:meshHeading | pubmed-meshheading:16030067... | lld:pubmed |
| pubmed-article:16030067 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16030067 | pubmed:articleTitle | Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. | lld:pubmed |
| pubmed-article:16030067 | pubmed:affiliation | Dept Fisiología, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain. | lld:pubmed |
| pubmed-article:16030067 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16030067 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16030067 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16030067 | lld:pubmed |
